CA2131553C - Use of alkylureas and hydroxyurea as contraceptive agents - Google Patents
Use of alkylureas and hydroxyurea as contraceptive agents Download PDFInfo
- Publication number
- CA2131553C CA2131553C CA002131553A CA2131553A CA2131553C CA 2131553 C CA2131553 C CA 2131553C CA 002131553 A CA002131553 A CA 002131553A CA 2131553 A CA2131553 A CA 2131553A CA 2131553 C CA2131553 C CA 2131553C
- Authority
- CA
- Canada
- Prior art keywords
- contraceptive
- butylurea
- foam
- enhanced
- contraceptive means
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
Abstract
This invention is directed to the use of alkylureas, such as butylurea, ethylurea, propylurea or methylurea, and to the use of hydroxyurea as contraceptive agents. Alkylureas and/or hydroxyurea may be used either alone or with a pharmaceutically accept-able carrier, and may be used in conjunction with conventional contraceptive means to abrogate sperm motility.
Description
VI~O 93/ 1767 ~ . , pS."Tf ~JS93/01992 '~~.~:~.~~~
USE O~' ALKYLU~tEAS ~1ND 1HYDROXYUREA
A~ CnNTRACEPTIVE AGENTG
FTFT T) ~F THF,~ INVENTI(~~1 This invention relates to the use of alkylureas, particularly butylurea, and/or hydro~yurea as contraceptive agents. Specifically, it is directed to the use of alkylureas and/or hydroxyurea as agents for abrogating sperm motil~.ty.
~~Cxc;RC~t)° T~'~NTI N
U.S. Patent NO. x,880,836 describes the use Of alkylureas as anti-viral agents effective against Herpes I virus, Herpes II virus and the AIDS virus.
This patent further describes methods of treating viral infection in media such as blood supply, blood bank and surfaces of all kinds by administering to such media an anti-virally effective amount of 1~ alkylureas. The present invention describes the use of alkylureas as well as hydroayurea as contraceptive agents and that hydroxyurea may also be used as anti-viral agents.
Tt is an object of this invention to provide ~0 methods of abrogating sperm motility utilizing alkylureas and/or hydro~yurea.
It is a further object of this invention to provide contraceptive compositions containing WO 93/17675 . P~ffU~93/01~92 alkylureas and/or hydroxyurea sArhich compositions are useful in abrogating sperm motility, and methods of making such compositions.
It is another object of this invention to provide contraceptive compositions effective in abrogating sgerm motility, which compositions may be used either alone or in con'unction with conventional contraceptive means, and methods of making such compositions. .
l0 THE IE~~10~
'his invention is directed to the use of alkylureas, particularly butylurea, and/or hydroa~yurea as contraceptive agents. such contraceptive agents being capable of abrogating sperm motility.
Z5 Alkylureas and/or hydroxyurea may be used either alone or in conjunction with conventional contraceptive means as contraceptive agents.
~T~~n n~sc~TP~°~~~ of ~E zr~~~~~~~a This invention is directed to methods of 20 abrogating sperm motility, contraceptive compositions which are useful in abrogating sperm motility and capable of enhancing the contraceptive capabilities of conventional contraceptive means, methods of making such contraceptive compositions, methods of enhancing 25 the contraceptive capabilities of conventional contraceptive means and enhanced conventional contraceptive means.
Specifically, this invention is directed to W~ 93117675 ~ "~ ~ ~~ ~ j ~ Pf.'T/1JS93/01992 the use of alkylureas, such as butylurea, ethylurea, propylurea or methylurea. and/or the use of hydroxyurea as contraceptive agents capable of abrogating sperm motility.
The inventor has discovered that when sperm is put into contact with at least one alkylurea ar with hydro~eyurea, the sperm's motility is abrogated.
Hence, alkylureas and/or hydrozyurea may be used as contraceptive agents. These ureas may be used in conjunction with pharmaceutically acceptable carriers to form contraceptive compositions which contraceptive compositions may be used alone as contraceptive agents, or in conjunction with a conventional contraceptive means.
For example, at least one alkylurea and/or hydroxyurea may be combined with a pharmaceutically acceptable carrier to form a contraceptive composition. Such pharmaceutically acceptable carrier may be a contraceptive or vaginal foam. In a preferred embodiment of this invention, at least one alkylurea and/or hydroxyurea is combined with Semicid contraceptive foam or any other contraceptive or vaginal foam which contains the active ingredient I~onoxynol-9. The resulting contraceptive composition will have an enhanced ability to abrogate sperm motility.
Such contraceptive compositions, or alkylureas and/or hydroxyurea alone, may be used to coat WO 93/ ~ 7675 ~ ~ J ~ P("T/lJS93/01992 conventional contraceptive means, such as condoms, diaphragms or sponges. The coating of such conventional contraceptive means with either such contraceptive composition, or with alkylureas and/or hydro~yurea alone, will result in enhanced conventional contraceptive means. The coating of the conventional contraceptive means with alkylureas and/or hydroxyurea may be performed by priming the conventional contraceptive means using a priming treatment, such as flame. oxidizing acid, corona ' discharge Or plasma, coating the premed means wgth a lir~uid solution of hydrogPl polymer and absorbing the alkylureas and/or hydroxyurea into the hydrogel polymer. Hydrogel polymer coating methods are, discussed in iJ.~. Patent Nos. 4.575,476, 4.499,154, and 4,482,577. The coating of conventional contraceptive means with alkylureas and/or hydra~yurea, utilizing the hydrogel polymer coating method, will result in enhanced conventional contraceptive means with increased contraceptive capabilities. When sperm is put into contact with such coated contraceptive means, the motility of the sperm is abrogated. ~Ience, alkylureas, such as butylurea, ethylurea, propylurea and methylurea. as well as hydro~yurea may be used as contraceptive agents>
In addition, hydroxyurea may be an effective anti-viral agent, arid may be used to inhibit the vvc~ 9~ia°rs~s '~; ~ ~'~ ~j ~ ~~ Pc~rfus93>om~2 transmission of ~IIV. Hence, if a contraceptive composition includes hydro~yurea, that composition may be effective in both abrogating sperm motility and irahibiting the transmission of HIV.
USE O~' ALKYLU~tEAS ~1ND 1HYDROXYUREA
A~ CnNTRACEPTIVE AGENTG
FTFT T) ~F THF,~ INVENTI(~~1 This invention relates to the use of alkylureas, particularly butylurea, and/or hydro~yurea as contraceptive agents. Specifically, it is directed to the use of alkylureas and/or hydroxyurea as agents for abrogating sperm motil~.ty.
~~Cxc;RC~t)° T~'~NTI N
U.S. Patent NO. x,880,836 describes the use Of alkylureas as anti-viral agents effective against Herpes I virus, Herpes II virus and the AIDS virus.
This patent further describes methods of treating viral infection in media such as blood supply, blood bank and surfaces of all kinds by administering to such media an anti-virally effective amount of 1~ alkylureas. The present invention describes the use of alkylureas as well as hydroayurea as contraceptive agents and that hydroxyurea may also be used as anti-viral agents.
Tt is an object of this invention to provide ~0 methods of abrogating sperm motility utilizing alkylureas and/or hydro~yurea.
It is a further object of this invention to provide contraceptive compositions containing WO 93/17675 . P~ffU~93/01~92 alkylureas and/or hydroxyurea sArhich compositions are useful in abrogating sperm motility, and methods of making such compositions.
It is another object of this invention to provide contraceptive compositions effective in abrogating sgerm motility, which compositions may be used either alone or in con'unction with conventional contraceptive means, and methods of making such compositions. .
l0 THE IE~~10~
'his invention is directed to the use of alkylureas, particularly butylurea, and/or hydroa~yurea as contraceptive agents. such contraceptive agents being capable of abrogating sperm motility.
Z5 Alkylureas and/or hydroxyurea may be used either alone or in conjunction with conventional contraceptive means as contraceptive agents.
~T~~n n~sc~TP~°~~~ of ~E zr~~~~~~~a This invention is directed to methods of 20 abrogating sperm motility, contraceptive compositions which are useful in abrogating sperm motility and capable of enhancing the contraceptive capabilities of conventional contraceptive means, methods of making such contraceptive compositions, methods of enhancing 25 the contraceptive capabilities of conventional contraceptive means and enhanced conventional contraceptive means.
Specifically, this invention is directed to W~ 93117675 ~ "~ ~ ~~ ~ j ~ Pf.'T/1JS93/01992 the use of alkylureas, such as butylurea, ethylurea, propylurea or methylurea. and/or the use of hydroxyurea as contraceptive agents capable of abrogating sperm motility.
The inventor has discovered that when sperm is put into contact with at least one alkylurea ar with hydro~eyurea, the sperm's motility is abrogated.
Hence, alkylureas and/or hydrozyurea may be used as contraceptive agents. These ureas may be used in conjunction with pharmaceutically acceptable carriers to form contraceptive compositions which contraceptive compositions may be used alone as contraceptive agents, or in conjunction with a conventional contraceptive means.
For example, at least one alkylurea and/or hydroxyurea may be combined with a pharmaceutically acceptable carrier to form a contraceptive composition. Such pharmaceutically acceptable carrier may be a contraceptive or vaginal foam. In a preferred embodiment of this invention, at least one alkylurea and/or hydroxyurea is combined with Semicid contraceptive foam or any other contraceptive or vaginal foam which contains the active ingredient I~onoxynol-9. The resulting contraceptive composition will have an enhanced ability to abrogate sperm motility.
Such contraceptive compositions, or alkylureas and/or hydroxyurea alone, may be used to coat WO 93/ ~ 7675 ~ ~ J ~ P("T/lJS93/01992 conventional contraceptive means, such as condoms, diaphragms or sponges. The coating of such conventional contraceptive means with either such contraceptive composition, or with alkylureas and/or hydro~yurea alone, will result in enhanced conventional contraceptive means. The coating of the conventional contraceptive means with alkylureas and/or hydroxyurea may be performed by priming the conventional contraceptive means using a priming treatment, such as flame. oxidizing acid, corona ' discharge Or plasma, coating the premed means wgth a lir~uid solution of hydrogPl polymer and absorbing the alkylureas and/or hydroxyurea into the hydrogel polymer. Hydrogel polymer coating methods are, discussed in iJ.~. Patent Nos. 4.575,476, 4.499,154, and 4,482,577. The coating of conventional contraceptive means with alkylureas and/or hydra~yurea, utilizing the hydrogel polymer coating method, will result in enhanced conventional contraceptive means with increased contraceptive capabilities. When sperm is put into contact with such coated contraceptive means, the motility of the sperm is abrogated. ~Ience, alkylureas, such as butylurea, ethylurea, propylurea and methylurea. as well as hydro~yurea may be used as contraceptive agents>
In addition, hydroxyurea may be an effective anti-viral agent, arid may be used to inhibit the vvc~ 9~ia°rs~s '~; ~ ~'~ ~j ~ ~~ Pc~rfus93>om~2 transmission of ~IIV. Hence, if a contraceptive composition includes hydro~yurea, that composition may be effective in both abrogating sperm motility and irahibiting the transmission of HIV.
Fresh sperm was obtained from four healthy volunteers. The level of sperm motility for each of the samples was recorded in a hemacount-chamber and scored as normal, reduced or absent.
,~.8~ Next, solutions of butylurea in phosphate buffered saline ~PHS) at concentrations of 100 mMol, mMol and 10 mMol were added to the sperm samples.
The sperm was then tested 1 to 2 minutes, 15 minutes and 1 hour after incubation with the butylurea. The 15 results are set out in Table I belowm ~A~~~ I
~~perm l~otilitv Donor Af~~~ 1~2' ~.' 1 hour 1 reduced absent 45% absent 100%
2 reduced absent 45% absent 100%
3 reduced ~ absent 45% absent 100%
9 reduced absent 45% absent 100%
After 1-2 minutes of incubation with the butylurea, the sperm motility of all four volunteers was reduced. After 15 minutes of incubation with butylurea, the sperm motility of all four individuals was reduced 45%. After 1 hour of incubation with butylurea, the sperm motility of all four volunteers PC'ftUS93/(D1992 WO 931d767S
,~.8~ Next, solutions of butylurea in phosphate buffered saline ~PHS) at concentrations of 100 mMol, mMol and 10 mMol were added to the sperm samples.
The sperm was then tested 1 to 2 minutes, 15 minutes and 1 hour after incubation with the butylurea. The 15 results are set out in Table I belowm ~A~~~ I
~~perm l~otilitv Donor Af~~~ 1~2' ~.' 1 hour 1 reduced absent 45% absent 100%
2 reduced absent 45% absent 100%
3 reduced ~ absent 45% absent 100%
9 reduced absent 45% absent 100%
After 1-2 minutes of incubation with the butylurea, the sperm motility of all four volunteers was reduced. After 15 minutes of incubation with butylurea, the sperm motility of all four individuals was reduced 45%. After 1 hour of incubation with butylurea, the sperm motility of all four volunteers PC'ftUS93/(D1992 WO 931d767S
was completely abrogated. This shows that butylurea is capable of completely abrogating sperm motility.
Although the invention herein has been described with reference to a particular embodiment.
at is to be understood that these embodiments are merely illustrative of various aspects of the invention. Thus, it is to be understood that numerous modifications may be made in the illustrative embodiments and other arrangements may be devised ~1j0° without departing from the spirit and scope of the invention.
Although the invention herein has been described with reference to a particular embodiment.
at is to be understood that these embodiments are merely illustrative of various aspects of the invention. Thus, it is to be understood that numerous modifications may be made in the illustrative embodiments and other arrangements may be devised ~1j0° without departing from the spirit and scope of the invention.
Claims (35)
1. A method of abrogating sperm motility which comprises putting sperm into contact with butylurea either alone or in conjunction with a pharmaceutically acceptable carrier.
2. The method according to Claim 1 wherein the pharmaceutically acceptable carrier is a contraceptive foam or a vaginal foam.
3. A method of enhancing the contraceptive capabilities of conventional contraceptive means which comprises coating a conventional contraceptive means with a contraceptive composition comprising butylurea either alone or in conjunction with a pharmaceutically acceptable carrier.
4. The method according to Claim 3 wherein the pharmaceutically acceptable carrier is a contraceptive or a vaginal foam.
5. The method according to Claim 3 wherein the conventional contraceptive means is selected from the group consisting of a condom, a diaphragm or a sponge.
6. The method according to Claim 3 wherein the coating of the conventional contraceptive means is performed by priming the conventional contraceptive means with a conventional priming treatment, coating the primed conventional contraceptive means with a liquid solution of hydrogel polymer and absorbing the contraceptive composition into the hydrogel polymer.
7. An enhanced conventional contraceptive means which comprises a conventional contraceptive means coated with butylurea either alone or in conjunction with a pharmaceutically acceptable carrier.
8. The enhanced conventional contraceptive means according to Claim 7 wherein the pharmaceutically acceptable carrier is a contraceptive or a vaginal foam.
9. The enhanced contraceptive means according to Claim 7 wherein the conventional contraceptive means is selected from the group consisting of a condom, a diaphragm or a sponge.
10. An enhanced conventional contraceptive means which comprises a contraceptive foam or a vaginal foam and butylurea.
11. The method of Claim 2 which comprises putting sperm into contact with butylurea and a contraceptive foam.
12. The method of Claim 2 which comprises putting sperm into contact with butylurea and a vaginal foam.
13. The method of Claim 11 wherein the contraceptive foam contains Nonoxynol-9.
14. The method of Claim 12 wherein the vaginal foam contains Nonoxynol-9.
15. The method of Claim 4 wherein the contraceptive composition comprises butylurea and a contraceptive foam.
16. The method of Claim 4 wherein the contraceptive composition comprises butylurea and a vaginal foam.
17. The method of Claim 15 wherein the contraceptive foam contains Nonoxynol-9.
18. The method of Claim 16 wherein the vaginal foam contains Nonoxynol-9.
19. The method of Claim 5 wherein the conventional contraceptive means is a condom.
20. The method of Claim 5 wherein the conventional contraceptive means is a diaphragm.
21. The method of Claim 5 wherein the conventional contraceptive means is a sponge.
22. The enhanced conventional contraceptive means of Claim 8 which comprises a conventional contraceptive means coated with butylurea and a contraceptive foam.
23. The enhanced conventional contraceptive means of Claim 8 which comprises a conventional contraceptive means coated with butylurea and a vaginal foam.
24. The enhanced conventional contraceptive means of Claim 22 wherein the contraceptive foam contains Nonoxynol-9.
25. The enhanced conventional contraceptive means of Claim 23 wherein the vaginal foam contains Nonoxynol-9.
26. The enhanced conventional contraceptive means of Claim 9 wherein the conventional contraceptive means is a condom.
27. The enhanced conventional contraceptive means of Claim 9 wherein the conventional contraceptive means is a diaphragm.
28. The enhanced conventional contraceptive means of Claim 9 wherein the conventional contraceptive means is a sponge.
29. The enhanced conventional contraceptive means of Claim 10 which comprises a contraceptive foam and butylurea.
30. The enhanced conventional contraceptive means of Claim 10 which comprises a vaginal foam and butylurea.
31. The enhanced conventional contraceptive means of Claim 29 wherein the contraceptive foam contains Nonoxynol-9.
32. The enhanced conventional contraceptive means of Claim 30 wherein the vaginal foam contains Nonoxynol-9.
33. The method of Claim 3 wherein butylurea is present in an amount effective to abrogate sperm motility.
34. The enhanced conventional contraceptive means of Claim 7 wherein butylurea is present in an amount effective to abrogate sperm motility.
35. The enhanced conventional contraceptive means of Claim 10 wherein butylurea is present in an amount effective to abrogate sperm motility.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/847,193 US5229423A (en) | 1992-03-06 | 1992-03-06 | Use of butylurea as a contraceptive agent |
| US07/847,193 | 1992-03-06 | ||
| PCT/US1993/001992 WO1993017675A1 (en) | 1992-03-06 | 1993-03-05 | Use of alkylureas and hydroxyurea as contraceptive agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2131553A1 CA2131553A1 (en) | 1993-09-16 |
| CA2131553C true CA2131553C (en) | 2003-07-08 |
Family
ID=25300032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002131553A Expired - Fee Related CA2131553C (en) | 1992-03-06 | 1993-03-05 | Use of alkylureas and hydroxyurea as contraceptive agents |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5229423A (en) |
| EP (1) | EP0627914B1 (en) |
| JP (1) | JPH08502239A (en) |
| AT (1) | ATE218332T1 (en) |
| AU (1) | AU3791193A (en) |
| CA (1) | CA2131553C (en) |
| DE (1) | DE69331987T2 (en) |
| DK (1) | DK0627914T3 (en) |
| ES (1) | ES2176200T3 (en) |
| WO (1) | WO1993017675A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229423A (en) * | 1992-03-06 | 1993-07-20 | Albert Einstein College Of Medicine Of Yeshiva University | Use of butylurea as a contraceptive agent |
| US20020061864A1 (en) * | 1994-09-22 | 2002-05-23 | Geda International Marketing Company Ltd. | Antiseptic spermicidal composition and means for its application |
| NL9500216A (en) * | 1995-02-06 | 1996-09-02 | Bio Pharma Sciences Bv | Pharmaceutical composition for the treatment of herpes. |
| DE19606355A1 (en) * | 1996-02-12 | 1997-08-14 | Schering Ag | Contraceptive release systems with antiviral and / or antibacterial effects |
| US9662360B2 (en) | 2008-10-09 | 2017-05-30 | Meritus Corporation | Treatment of herpes, pseudomonas, staph, and hepatitis |
| US20090191288A1 (en) * | 1996-02-12 | 2009-07-30 | Squires Meryl J | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases |
| US6011013A (en) * | 1997-06-20 | 2000-01-04 | Oregon Health Sciences University | Contraceptive compositions and methods |
| US6432941B1 (en) | 1998-01-20 | 2002-08-13 | Parker Hughes Institute | Vanadium compounds for treating cancer |
| US6051603A (en) * | 1998-01-20 | 2000-04-18 | Wayne Hughes Institute | Vanadium (IV) metallocene complexes having sperm motility inhibiting activity |
| US6245808B1 (en) | 1998-11-05 | 2001-06-12 | Parker Hughes Institute | Oxy-vanadium (IV) complexes having spermicidal activity |
| US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
| US6211243B1 (en) | 1999-09-22 | 2001-04-03 | B. Ron Johnson | Methods for treating cold sores with anti-infective compositions |
| US8173709B2 (en) * | 1999-09-22 | 2012-05-08 | Quadex Pharmaceuticals, Llc | Anti-infective methods for treating pathogen-induced disordered tissues |
| US6759434B2 (en) | 1999-09-22 | 2004-07-06 | B. Ron Johnson | Anti-infective compositions, methods and systems for treating disordered tissue |
| CN100342917C (en) * | 2002-08-20 | 2007-10-17 | Alda医药公司 | A wide spectrum disinfectant |
| US20050272819A1 (en) * | 2003-07-31 | 2005-12-08 | Arye Rubinstein | Use of alkylureas for treating acne |
| AU2004267383A1 (en) * | 2003-08-14 | 2005-03-03 | The Bio Balance Corporation | Bacterial strains, compositions including same and probiotic use thereof |
| EP2271328A4 (en) * | 2008-03-20 | 2011-09-07 | Alda Pharmaceuticals Corp | Antiseptic compositions for the treatment of infections |
| US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
| US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
| US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
| EP3621603A4 (en) * | 2017-05-08 | 2021-01-20 | Meharry Medical College | Hydroxyurea to enhance sperm cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3813695A (en) * | 1973-02-21 | 1974-06-04 | D Podell | Surgical glove |
| US4482577A (en) * | 1980-12-16 | 1984-11-13 | Albert Goldstein | Coating process of elastomeric material |
| US4499154A (en) * | 1982-09-03 | 1985-02-12 | Howard L. Podell | Dipped rubber article |
| DE3765145D1 (en) * | 1986-03-12 | 1990-10-31 | Euro Celtique Sa | RECEPTION PREVIOUS COMPOSITION. |
| FR2598916B1 (en) * | 1986-05-22 | 1988-09-09 | Atlantic Pharma Prod | FLUORINATED CHEMICAL COMPOUND USED IN A LOCAL CONTRACEPTION METHOD AND FLUORINATED LOCAL CONTRACEPTIVE COMPOSITION, ESPECIALLY SPERMICIDE |
| US4880836A (en) * | 1988-03-11 | 1989-11-14 | Danek Elbaum | Antiviral amphiphilics |
| US5229423A (en) * | 1992-03-06 | 1993-07-20 | Albert Einstein College Of Medicine Of Yeshiva University | Use of butylurea as a contraceptive agent |
-
1992
- 1992-03-06 US US07/847,193 patent/US5229423A/en not_active Expired - Lifetime
-
1993
- 1993-03-05 AT AT93907234T patent/ATE218332T1/en not_active IP Right Cessation
- 1993-03-05 ES ES93907234T patent/ES2176200T3/en not_active Expired - Lifetime
- 1993-03-05 JP JP5515906A patent/JPH08502239A/en not_active Ceased
- 1993-03-05 CA CA002131553A patent/CA2131553C/en not_active Expired - Fee Related
- 1993-03-05 DK DK93907234T patent/DK0627914T3/en active
- 1993-03-05 EP EP93907234A patent/EP0627914B1/en not_active Expired - Lifetime
- 1993-03-05 DE DE69331987T patent/DE69331987T2/en not_active Expired - Fee Related
- 1993-03-05 AU AU37911/93A patent/AU3791193A/en not_active Abandoned
- 1993-03-05 WO PCT/US1993/001992 patent/WO1993017675A1/en active IP Right Grant
- 1993-06-03 US US08/071,723 patent/US5387611A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5229423A (en) | 1993-07-20 |
| WO1993017675A1 (en) | 1993-09-16 |
| CA2131553A1 (en) | 1993-09-16 |
| DE69331987D1 (en) | 2002-07-11 |
| JPH08502239A (en) | 1996-03-12 |
| DK0627914T3 (en) | 2002-09-23 |
| ES2176200T3 (en) | 2002-12-01 |
| EP0627914A4 (en) | 1997-01-29 |
| US5387611A (en) | 1995-02-07 |
| ATE218332T1 (en) | 2002-06-15 |
| EP0627914B1 (en) | 2002-06-05 |
| AU3791193A (en) | 1993-10-05 |
| EP0627914A1 (en) | 1994-12-14 |
| DE69331987T2 (en) | 2003-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2131553C (en) | Use of alkylureas and hydroxyurea as contraceptive agents | |
| US4804674A (en) | Vaginal pharmaceutical composition | |
| US5209865A (en) | Conditioning solution for contact lenses and a method of using the same | |
| US4424232A (en) | Treatment of herpes simplex | |
| CA2302232C (en) | Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent | |
| Mellor et al. | Vesicant burns | |
| AU657387B2 (en) | Bloodbag and method of making same | |
| EP0692483A4 (en) | Cell adhesion inhibitor and thienotriazolodiazepine compound | |
| ES2143301T3 (en) | BIOCOMPATIBLE COMPOSITIONS. | |
| Fisher et al. | Allergic contact sensitivity to benzalkonium chloride: cutaneous, ophthalmic, and general medical implications | |
| EP0441003A2 (en) | Ophthalmic medication | |
| WO2001035906A3 (en) | Personal care articles comprising a hydrophilic conditioning agent exhibiting a defined leaching value | |
| KR960704911A (en) | 2 ', 5'-oligoadenylate-2', 3'-cyclophosphate (2 ', 5'-OLIGOADENYLATE-2', 3'-CYCLOPHOSPHATES) | |
| US6440411B2 (en) | Ophthalmic product colored with blue alga extract | |
| DK0655911T3 (en) | Ophthalmological preparation | |
| US5013544A (en) | Contraceptive methods and compositions | |
| ES2060147T3 (en) | NEW CONCENTRATED AQUEOUS EMULSIONS, THEIR PREPARATION PROCEDURE AND THEIR APPLICATION IN THE PESTICIDE FIELD. | |
| Laibson et al. | Double controlled comparison of IDU and trifluorothymidine in thirty-three patients with superficial herpetic keratitis. | |
| Poloniecki et al. | Further analysis of the Hills and Armitage enuresis data | |
| CA2134413A1 (en) | Use of Hydroxychloroquine for Treatment of Graft-Versus-Host Disease | |
| CA1254515A (en) | Contraceptive methods | |
| US3452139A (en) | Method of treating seborrheic dermatitis with n,n-diethyl-m-toluamide | |
| Babar et al. | Release and permeation studies of propranolol hydrochloride from hydrophilic polymeric matrices | |
| TH13559A (en) | Pharmaceutical constituents used in the treatment of glaucoma | |
| TH8676B (en) | Pharmaceutical constituents used in the treatment of glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed | ||
| MKLA | Lapsed |
Effective date: 20060306 |